Kornimate/medical-research-clean huggingface dataset:
laparascopic vs. laparotomy management of neonatal duodenal atresia

Conditions: Congenital Duodenal Atresia

Summary: congenital duodenal atresia is a common cause of neonatal obstruction affecting 1 in 5000-10000 neonates. laparoscopic management of this malformation is becoming increasingly common. however, few comparative studies exist and are often monocentric including few patients. this study will be multicentric, international and comparative to determine the place of laparoscopic surgery in the management of congenital duodenal atresia.


Eligibility criteria:
inclusion criteria: * minor subject * subject having undergone neonatal surgery for congenital duodenal atresia or stenosis in the different participating centers between january 2009 and december 2019 * subject (and/or his/her parental authority) who has not expressed, after information, his/her opposition to the reuse of his/her data for the purpose of this research criteria for non-inclusion: * subject (and/or his/her parental authority) who has indicated, after information, his/her opposition to the re-use of his/her data for the purposes of this research * conversion linked to a renunciation of the surgeon, procedure not started (optical introduction, unfeasibility by the surgeon due to lack of experience or technical impossibility)

Keywords: congenital duodenal atresia neonatal obstruction laparascopic laparotomy neonatal duodenal atresia
improving cesarean section experience through hypnotherapy

Conditions: Cesarean Section; Pain; Anxiety

Summary: cesarean section rates continue to increase worldwide, particularly in middle- and high-income countries. in france, the rate has now stabilized around 20 %. cesarean section is a particular way of giving birth, sometimes desired, but sometimes feared. if some women do not feel affected by this way of giving birth, it is more difficult for others to live with. in this way, not being able to give birth trough natural way may be disturbing in motherhood. at la rochelle hospital, more than 230 healthcare providers have been trained according to erickson's hypnosis methodology. among them, 40 are part of the anesthesia department and a committee oversees the hypnotherapist activities in pain management. the objective of the present study is to assess the benefit of hypnosis session for improving experience and reducing anxiety in women giving birth through surgery.

nonpharmacological approaches for pain management, either as a primary method or as a complement to pharmacological approaches, are suggested for a better perinatal management. the investigators assessed the use of conversational hypnotic induction and therapeutic suggestions during cesarean section as a complement to pharmacological strategy. women giving birth through scheduled or unplanned cesarean section and who accepted hypnotherapy session were compared to a control group.

Eligibility criteria:
inclusion criteria: * over 18 * scheduled or unplanned cesarean section * informed consent exclusion criteria: * refusal of the patient to participate in the study * not french speaking * patients under guardianship
the del nido versus cold blood cardioplegia in aortic valve replacement

Conditions: Aortic Valve Disease; Ischemia-reperfusion Injury

Summary: a group of 150 patients undergoing aortic valve replacement procedure will be randomized either into del nido cardioprotection protocol (75 participants) or into the cold blood cardioplegia protocol (75 participants). the intraoperative and perioperative outcomes of using each solution will be presented and compared (see the endpoints).

the del nido cardioplegia was developed by pedro del nido and his team at the university of pittsburgh in 1990s. it was primarily designed for children and it has been used in pediatric cardiac surgery in boston's children hospital since 1994. there are few studies regarding the del nido cardioplegia. a prospective, randomized trial was designed to determine the efficiency of the del nido cardioplegia when compared to multidose cold blood cardioplegia in cardiac procedures with short and moderate cross-clamp times. for the analysis of two cardioprotection protocols, it is essential to compare groups equal in terms of the surgery and perioperative care, with the same surgical risk and cross-clamp time. the research required elimination of all the unnecessary variables. the patients undergoing aortic valve replacement procedure were selected as a study population. a group of 150 patients will be randomized either into del nido cardioprotection protocol (75 participants) or into the cold blood cardioplegia protocol (75 participants). the intraoperative and perioperative outcomes of using each solution will be presented and compared (see the endpoints).

Eligibility criteria:
inclusion criteria: * qualification for isolated aortic valve replacement * age\>18 years * given consent for the study exclusion criteria: * reoperation * allergy to lidocaine * coronary artery disease requiring surgical or percutaneous intervention * pregnancy * ejection fraction\<30% * massive aortic calcification ("porcelain aorta")

Keywords: del nido cardioplegia aortic valve
a safety and efficacy study of a recombinant factor ix in patients with severe hemophilia b

Conditions: Hemophilia B

Summary: this study will examine the safety and efficacy of a recombinant coagulation factor ix albumin fusion protein (rix-fp) for the control and prevention of bleeding episodes in subjects who have previously received factor replacement therapy for hemophilia b. the study consists of a screening period, a pharmacokinetic (pk) period, followed by approximately a 5 month treatment period. subjects will receive weekly routine prophylactic therapy and on-demand treatment for bleeding episodes. in addition, subjects who are not on routine factor replacement therapy prior to the study will receive only on-demand treatment for bleeding episodes.


Eligibility criteria:
inclusion criteria: * male subjects, 12 to 65 years old * severe hemophilia b (fix activity of ≤ 2%) * subjects who have received fix products (plasma-derived and/or recombinant fix) for \> 150 exposure days (eds) * no history of fix inhibitor formation, no detectable inhibitors at screening and no family history of inhibitors against fix * written informed consent for study participation obtained before undergoing any study specific procedures exclusion criteria: * known hypersensitivity to any fix product or hamster protein * known congenital or acquired coagulation disorder other than congenital fix deficiency * hiv positive subjects with a cd4 count \< 200/mm3 * low platelet count, abnormal kidney function, or liver disease * on-demand subjects experiencing less than 12 or 6 non-trauma induced bleeding episodes requiring treatment with a fix product during the previous 6 or 3 months, respectively * planned major surgical intervention during the study period
early transfusion of convalescent plasma in elderly covid-19 patients. to prevent disease progression.

Conditions: Coronavirus Disease 2019 )COVID-19)

Summary: older age is an independent poor outcome predictor among covid-19 hospitalized patients . among 72,314 covid-19 cases, case fatality rate (cfr) was 2.3% in total population, 8% in people aged 70 to 79, and 14.8% in those aged 80 and older. in the whole population, cfr was higher in people with comorbidities, ranging from 5-6% in persons with hypertension, chronic respiratory disease, diabetes or cancer, up to 10% in those with cardiovascular diseases. sars-cov-2 seems to be able to induce a functional exhaustion of specified t and nk lymphocyte subpopulations, breaking down antiviral immunity. one possible explanation is that the immune system of elderly people, might be exhausted by chronic stimulation associated with comorbidities and more susceptible to this sars-cov-2 effect. as a result, in these patients, the activation of the innate immune system might fail to produce an adequate adaptive response (i.e., virus-specific cd8+ t-cells). this results in persistent self-induced inflammation that eventually causes mortality. the investigators hypothesize that transfusing convalescent plasma (containing neutralizing antibodies) at an early phase of covid-19 infection could prevent or switch off the persistent inflammatory response elicited by the virus. the objective of this study are: * to demonstrate the superiority of covid-19 convalescent plasma (ccp) plus standard therapy (st) over st alone * to prevent progression of pneumonia in covid-19 patients aged ≥65 with chronic comorbidities * to decrease viral load * to raise anti-sars-cov-2 antibody titer in recipients


Eligibility criteria:
inclusion criteria: * age ≥ 65 * pneumonia at ct scan * pao2/fio2 ≥300 mmhg * presence of one or more comorbidities (consider the list provided in appendix a) * signed informed consent exclusion criteria: * age \< 65 * pao2/fio2 \< 300 mmhg * pending cardiopulmonary arrest * refusal to blood product transfusions * severe iga deficiency * any life-threatening comorbidity or any other medical condition which, in the opinion of the investigator, makes the patient unsuitable for inclusion
investigating the utility of remote index of microvascular resistance in patients with chronic total occlusion

Conditions: Chronic Total Occlusion

Summary: this is prospective cohort study in subjects with a planned percutaneous coronary intervention (pci) of their chronic total occlusion (cto). the study will enroll subjects who have been scheduled for a clinically-indicated cardiac catheterization, and will evaluate coronary microvascular function in all subjects meeting inclusion criteria with a coronary flow wire. evaluation of coronary microvascular function may be performed using indirect methods, however the rationale behind the present study is to directly measure microvascular function using direct coronary flow measurements, since the subjects in the study are to undergo a clinically-indicated cardiac catheterization. the overall purpose of the study is to define the presence and severity of coronary microvascular dysfunction subjects with cto. the study is designed to enroll 50 subjects with cto in the span of 3 years. there will be a 6-month assessment of the outcomes of death and cardiovascular death. as the study includes fda approved tests, there will be no safety endpoint per se, however there will be a mechanism for monitoring adverse events as will be described in detail.


Eligibility criteria:
inclusion criteria: * age ≥ 21 years * seen at university of chicago medical center with a planned pci of a single cto vessel * must have either stable angina or angina equivalent * must have a cto with a clear donor vessel supplying most of the collaterals. exclusion criteria: * subjects with a pacemaker or implantable cardioverter defibrillator * contraindication to cardiac mri, adenosine, heparin, or nitroglycerin * cardiac transplantation * estimated glomerular filtration rate (egfr) ≤ 30 ml/min/1.73m2, given the risk of contrast-induced nephropathy (cin) and nephrogenic systemic fibrosis (nsf) associated with iodinated and gadolinium-based contrast agents, respectively, in patients with significant renal dysfunction * women who may potentially be pregnant will receive a pregnancy test and be excluded if pregnant * vulnerable populations such as children, college students, prisoners, non-english speakers, and those with diminished decision-making capacity * inability or refusal to consent for the study.

Keywords: microvascular resistance percutaneous coronary intervention
systematic implementation of patient-centered care for alcohol use trial: beyond referral to treatment

Conditions: Alcohol Use Disorder; Unhealthy Alcohol Use

Summary: the systematic implementation of patient-centered care for alcohol use trial is a pragmatic, cluster-randomized, effectiveness-implementation trial testing two interventions in kaiser permanente washington to systematically implement shared decision-making with primary care patients with symptoms due to alcohol use: a primary care intervention and a centralized intervention. an anticipated 25 primary care clinics will be randomized to one of three conditions: usual care or the primary care or centralized interventions.


Eligibility criteria:
inclusion criteria: 1. adult primary care patients ≥18 years old on the day of a primary care appointment; and 2. ≥4 symptoms on the alcohol symptom checklist, or 2-3 symptoms on the alcohol symptom checklist with at least one symptom associated with high risk of progression to severe symptoms, documented in the electronic health record associated with the primary care appointment; and 3. high-risk drinking on the alcohol screening questionnaire (audit-c ≥7) on the day of the alcohol symptom checklist or in the prior 30 days documented in the electronic health record. exclusion criteria: 1. documented request to not participate in research, or 2. patient was eligible for the vanguard pilot study.

Keywords: patient-centered care shared decision-making population-based management quality improvement decision aid
the "motoric cognitive risk" syndrome in the canadian population

Conditions: Cognition Disorders in Old Age; Cardiovascular Diseases; Dementia

Summary: cognition and locomotion are two human abilities controlled by the brain. their decline is highly prevalent with aging, and is greater than the simple sum of their respective prevalence, suggesting a complex age-related interplay between cognition and locomotion. recently, a systematic review and meta-analysis has provided evidence that poor gait performance predicts dementia and, in particular, has demonstrated that "motoric cognitive risk" (mcr) syndrome, which has been described in cognitively healthy individuals and combines subjective cognitive complaint with objective slow gait speed, is a pre-dementia syndrome. the uniqueness of "motoric cognitive risk" (mcr)syndrome is that it does not rely on a complex evaluation or laboratory investigations. thus, it is easy to apply in population-based settings. the overall objective of the proposal is to examine the epidemiology of the newly reported "motoric cognitive risk" (mcr) syndrome, in the quebec population using the database of the nuage study.


Eligibility criteria:
inclusion criteria: * individuals eligible for this study will be participants of the nuage study exclusion criteria: * individuals not eligible for the nuage study * dementia * mobility disability * no information about cognitive complaint * no measure of walking speed
treatment in right colon diverticulitis patients

Conditions: Outcome

Summary: the right colon diverticula, unlike those in the left colon, contain all layers of the colon and is called the true diverticulum. perforation is observed less frequently due to its full thickness. conservative treatment can be applied unless complications such as abscess formation and free perforation occur. unlike the left, right colon diverticulitis has low complications and can be treated conservatively. the differential diagnosis of right colon diverticulitis should be kept in mind in order to prevent unnecessary surgeries. surgical treatment is inevitable in cases such as recurrent diverticulitis, generalized peritonitis, and suspected malignancy.

the right colon diverticula, unlike those in the left colon, contain all layers of the colon and is called the true diverticulum. perforation is observed less frequently due to its full thickness. conservative treatment can be applied unless complications such as abscess formation and free perforation occur. here, we aimed to discuss the results of conservative and surgical treatment for right colon diverticulitis in the light of the literature. 150 patients treated for colon diverticulitis between 2015-2020 were retrospectively screened. right colon diverticulitis detected incidentally, missing data, and left colon diverticulitis were excluded from the study. data of a total of 26 patients were accessed. unlike the left, right colon diverticulitis has low complications and can be treated conservatively. the differential diagnosis of right colon diverticulitis should be kept in mind in order to prevent unnecessary surgeries. surgical treatment is inevitable in cases such as recurrent diverticulitis, generalized peritonitis, and suspected malignancy

Eligibility criteria:
inclusion criteria: * diagnosed with right colon diverticulitis exclusion criteria: * left colon diverticulitis * right colon diverticulitis detected incidentally * lacking data

Keywords: diverticulum surgery appendicitis sigmoid volvulus caecum diverticulitis
zanubrutinib combined with r-chop regimen in the treatment of newly diagnosed dlbcl with high-risk factors

Conditions: Diffuse Large B Cell Lymphoma

Summary: this study is a prospective, open-label, single-arm phase ii clinical study to evaluate the safety and efficacy of zanubrutinib plus r-chop (zr-chop) as the first-line therapy for newly diagnosed diffuse large b-cell lymphoma patients with high-risk factors.


Eligibility criteria:
inclusion criteria: 1. histologically confirmed dlbcl patients have one of the following risk factors(including but not limited to double expression, extranodal involvement, high ki67, bulky)； 2. age ≥ 18 years old; 3. at least one measurable lesion (defined as lymph node lesion ≥15mm, extra-segmental lesions ≥ 10mm); 4. ecog performance status 0-2; 5. functions of major organs meet the following conditions: echocardiography left ventricular ejection fraction ≥50%; creatinine clearance ≥30 ml/min; alt and ast≤3 times the normal range； 6. hematopoietic function should meet the following conditions: platelet count ≥50×109/l; hemoglobin ≥ 8.0g /dl; absolute count of neutrophil (anc)≥1.0×109/l; 7. expected survival of ≧3 months exclusion criteria: 1. major surgery within 4 weeks before treatment; 2. severe organ dysfunction(including but not limited to complications of uncontrolled cardiovascular diseases, blood clotting disorders, connective tissue diseases, serious infectious diseases and other diseases); 3. patients who cannot cooperate with treatment or follow-up on time. 4. pregnant or lactating females; 5. any uncontrolled active systemic infection requiring intravenous (iv) antibiotics; 6. there was a history of other active malignant diseases within the 2 years prior to study entry, except for: (1) adequately treated cervical carcinoma in situ; (2) local skin basal cell carcinoma or squamous cell carcinoma; (3) previous malignant disease that is under control and has undergone local radical treatment (surgical or other forms). 7. history of severe hemorrhagic disorders, such as hemophilia a, hemophilia b, von willebrand's disease, or spontaneous bleeding requiring blood transfusion or other medical intervention 8. human immunodeficiency virus (hiv) infection or the following serological status reflecting the presence of active hepatitis b or c virus infection: a. hepatitis b surface antigen (hbsag) or hepatitis b core antibody (hbcab) are present. patients who are hbcab-positive, hbsag negative, have no hepatitis b virus (hbv) dna (\< 20 iu/ml), and agree to be monitored for hbv virus reactivation can be enrolled. antibodies to the hepatitis c virus (hcv) are present. hcv antibody-positive patients with no hcv rna detected could be included in the group. 9. the presence of any life-threatening disease, medical condition, or organ system dysfunction that the investigator believes may affect the subject's safety or pose a risk to the study. 10. the researchers think it is not suitable to participate in this experiment.
a study to assess efficacy and safety of jnj-77242113 compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis

Conditions: Plaque Psoriasis

Summary: the main purpose of this study is to assess how well jnj-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.


Eligibility criteria:
inclusion criteria: * diagnosis of plaque psoriasis, with or without psoriatic arthritis (psa), prior to the first administration of study intervention * total body surface area (bsa) greater than or equal to (\>=)10 percent (%) at screening and baseline * total psoriasis area and severity index (pasi) \>=12 at screening and baseline * total investigator global assessment (iga) \>=3 at screening and baseline * candidate for phototherapy or systemic treatment for plaque psoriasis exclusion criteria: * nonplaque form of psoriasis (for example \[e.g.\], erythrodermic, guttate, or pustular) * current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium) * known allergies, hypersensitivity, or intolerance to jnj-77242113, ustekinumab, or its excipients * major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study * transplanted organ (with exception of a corneal transplant greater than \[\>\] 12 weeks before the first administration of study intervention)
chronic pain attitudes medical and physiotherapy students

Conditions: Chronic Low Back Pain

Summary: this is an analysis of data collected from 2009-2014 from medical students at gcu and physiotherapy students at uog measuring attitudes towards patients with chronic low back pain and their functionality.

this is longitudinal study with the data collected from 2009-2014 from medical students and physiotherapy students at two different scottish universities measuring attitudes towards patients with chronic low back pain and their functionality. the outcome measure used was hc-pairs the original 15 point likert scale. data was analysed using spss (version 25). all data was found to be normally distributed. descriptive statistics were presented as mean (standard deviation). inferential statistics were carried out using a two-way anova with year of study and discipline of degree as independent variables with post hoc analysis. a p-value of \<0.05 was considered statistically significant.

Eligibility criteria:
inclusion criteria: -engaged in the 2009 physiotherapy degree at two scottish universities exclusion criteria: -anyone who is not on the above degree courses.

Keywords: attitudes chronic low back pain functionality healthcare professional students
a study to evaluate the long-term use of valsartan in children 6 months to 5 years old with hypertension

Conditions: Hypertension

Summary: the purpose of this study is to evaluate the efficacy, safety and tolerability of long-term use (up to 18 weeks) of valsartan in children 6 months to 5 years old with hypertension.


Eligibility criteria:
inclusion criteria * participants who qualified and entered the core study. * participants who participated in the core study, completed period 1 and were re-randomized in period 2 and continued for at least 3 days in period 2. exclusion criteria * participants who did not complete period 1 of the core study. * participants who were re-randomized in period 2 of core study but did not continue for =\> 3 days in period 2 of the core study. * participants who experienced any adverse events considered serious or drug related in the core study. * participants excluded from the core study.

Keywords: children pediatrics high blood pressure hypertension valsartan